A detailed history of Los Angeles Capital Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 930,132 shares of CHRS stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
930,132
Previous 209,460 344.06%
Holding current value
$1.46 Million
Previous $362,000 167.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$0.99 - $1.8 $713,465 - $1.3 Million
720,672 Added 344.06%
930,132 $967,000
Q2 2024

Aug 05, 2024

BUY
$1.58 - $2.51 $20,935 - $33,257
13,250 Added 6.75%
209,460 $362,000
Q1 2024

Apr 05, 2024

BUY
$2.02 - $3.14 $119,967 - $186,484
59,390 Added 43.41%
196,210 $468,000
Q4 2023

Feb 06, 2024

BUY
$1.59 - $3.85 $98,137 - $237,629
61,722 Added 82.19%
136,820 $455,000
Q3 2023

Nov 06, 2023

BUY
$3.74 - $5.45 $280,866 - $409,284
75,098 New
75,098 $280,000
Q2 2021

Aug 05, 2021

SELL
$12.95 - $15.41 $1.31 Million - $1.56 Million
-101,460 Closed
0 $0
Q1 2021

May 05, 2021

SELL
$14.42 - $21.39 $1.05 Million - $1.56 Million
-72,860 Reduced 41.8%
101,460 $1.48 Million
Q4 2020

Feb 04, 2021

SELL
$16.56 - $18.94 $23,184 - $26,516
-1,400 Reduced 0.8%
174,320 $3.03 Million
Q3 2020

Nov 02, 2020

SELL
$17.41 - $19.89 $392,787 - $448,738
-22,561 Reduced 11.38%
175,720 $3.22 Million
Q2 2020

Aug 05, 2020

BUY
$14.43 - $19.16 $478,109 - $634,828
33,133 Added 20.06%
198,281 $3.54 Million
Q1 2020

May 04, 2020

BUY
$11.67 - $22.53 $744,324 - $1.44 Million
63,781 Added 62.92%
165,148 $2.68 Million
Q4 2019

Feb 07, 2020

BUY
$16.33 - $21.37 $1.22 Million - $1.6 Million
74,987 Added 284.26%
101,367 $1.83 Million
Q3 2019

Nov 07, 2019

BUY
$16.3 - $23.37 $429,994 - $616,500
26,380 New
26,380 $534,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.